Previous research studies

The Unit has been conducting studies for over 20 years and has experience in the following areas:
• National & international studies
• Locally generated research
• Collaboration with the Medical Research Council (MRC), the Pharmaceutical Industry and other units across the UK and abroad

Examples of the types of studies we conduct include:
• Studies on new antiretroviral drugs
• Studies to explore different treatment strategies e.g. simplifying HIV treatment
• The management of treatment side effects and management of other medical conditions e.g. HIV and Heart, Kidney/Liver
• Studies where we observe the effect of HIV on people over time and
• The screening and treatment for Sexually Transmitted Infections (STIs)
• HIV prevention and transmission studies





0111 – Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
0112 – Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
0109 – Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
1089 – Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
1844 (Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF )
1489 (Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine )
1878 (Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide )
0109 (Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination)
0122 (Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection)
2055 (DISCOVER PrEP study)















START – Strategic Timing of AntiRetroviral Treatment





047 – A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
056 – Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity
058 – Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
060 (NEAT) – Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG).
Also see article printed in NAM
064 – Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over
IMPACT – NHS England PrEP study








POPPY SLEEP  (Sub study of POPPY)


Want to be part of our research?